PAREA’s response to the EU Biotech Act to Unlock Mental-Health Innovation

PAREA has submitted a response to the European Commission’s open call for evidence on the EU Biotech Act: “Shaping the EU Biotech Act to Unlock Mental-Health Innovation”

The upcoming EU Biotech Act aims to accelerate biotech innovation while safeguarding safety and sustainability. PAREA welcomes this ambition and has highlighted mental health as a critical priority.

While mental health conditions affect over 143 million Europeans, they remain one of the most under-innovated areas in healthcare, with few new treatments and persistent structural neglect.

Our response outlines five concrete recommendations to direct biotech policy toward this high-need, under-invested area, including: targeted support mechanisms for early-stage biotechs, with default access to regulatory support; more public-private funding opportunities, and a dedicated EU Mental Health Innovation Fund; building pan-European clinical trial capacity, notably via the Brain Health Partnership; and promoting data access and real-world evidence platforms to accelerate uptake and scale.

Europe has the policy window to lead in mental health innovation, shaping a values-based environment that serves both competitiveness and societal resilience.

🔗 Read our full submission: https://lnkd.in/dZU9Nqyc